21:32:10 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-29 Bokslutskommuniké 2024
2024-10-29 Kvartalsrapport 2024-Q3
2024-07-30 Kvartalsrapport 2024-Q2
2024-05-17 Ordinarie utdelning ZICC 0.00 SEK
2024-04-29 Kvartalsrapport 2024-Q1
2024-01-26 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-06-21 Ordinarie utdelning ZICC 0.00 SEK
2023-06-20 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-01-27 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning ZICC 0.00 SEK
2022-04-28 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2022-01-18 Extra Bolagsstämma 2022
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-28 Ordinarie utdelning ZICC 0.00 SEK
2021-04-27 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 Ordinarie utdelning ZICC 0.00 SEK
2020-06-16 Årsstämma 2020
2020-04-17 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-20 Årsstämma 2019
2019-05-10 Ordinarie utdelning ZICC 0.00 SEK
2019-05-09 Kvartalsrapport 2019-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst versamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2022-12-16 20:00:00

Ziccum AB has been awarded non-dilutive funding of 10 MSEK by Eurostars for a joint application with the Institute of Computational Physics (ICP) at the School of Engineering at Zurich University of Applied Sciences (ZHAW). The project (application # 2,199 LaPaSim) is to apply 3D-modelling to Ziccum’s ambient drying system for biopharmaceuticals, LaminarPace, resulting in a digital twin. International competition for the funding was intense, and the proposal was one of the highest-ranked applications.

On September 14th, 2022 Ziccum and ZHAW announced their joint Eurostars application for funding towards a project applying 3D-modelling and developing a Digital twin of LaminarPace. Ziccum has now received notification that the project has been awarded the maximum 10 MSEK in funding. The project begun in June 2022 and will run over three years, where Ziccum is engaging the Research Area Multiphysics Modeling and Imaging team of ICP at ZHAW’s School of Engineering, led by Prof. Dr. Gernot Boiger, for advanced 3D-modeling.

The project is accelerating the industrial development, tech transfer and scaleout of LaminarPace as a unit of pharmaceutical production. As an ambient drying technology, LaminarPace uniquely is drying biopharmaceuticals by mass transfer instead of heat transfer, avoiding heat stress as well as mechanical stress to the delicate active ingredients – thus enabling high yields, thermostability and processing benefits.

Competition for the Eurostars funding was intense. The joint proposal was praised for its quality and strong business plan by the Eurostars evaluation team who pointed out the “very tough international assessment the applications go through”. The joint proposal was one of the highest-ranking projects.

The successful application is a firm validation of Ziccum’s sharpened strategic focus, technology development ambitions and new business plan. This plan encompasses critical technology optimization and the offering of new formulation and technology licenses to pharma, biotech and drug manufacturing partners.

Ziccum CEO Ann Gidner: “We are indeed happy and proud to have been awarded this grant, thanks to a high-ranking proposal developed in close collaboration with the ZHAW expert team. It is an excellent validation of our strategic focus and newly developed business plan. We used no external agency to produce this proposal - it was the product of our combined internal expertise. We look forward to moving ahead together on this important project.”

Ziccum Chairman Fredrik Sjövall: “I congratulate Ann and our team for their outstanding proposal and focused technology development. This is also a welcome financial reinforcement for Ziccum. This project is at an exciting stage in development, and I look forward to seeing it move ahead.”

About ICP and ZHAW

The Research Area Multiphysics Modeling and Imaging team of the ICP at at the School of Engineering at ZHAW is made up of 20 simulation experts, physicists, mathematicians and engineers led by Prof. Dr. Gernot Boiger. The team has carried out projects modeling particle flow across industries including pharmaceuticals, aerospace, energy, automotive and more.

About Eurostars

The Eurostars organization specializes in projects that partner SMEs such as Ziccum with larger companies, universities and research organizations. It funds R&D collaborations across 37 member countries. Eurostars is co-funded by the EU Horizon 2020 Framework Programme and EUREKA, the world’s largest public network for international cooperation in R&D and innovation.

The above is information that Ziccum is obliged to make public pursuant to EU Market Abuse Regulations (MAR). The information was submitted for publication, through the agency of the contact persons set out above, on 2022-12-16 at 20:00 CEST.